QCT and Robin.io Announce Strategic Partnership to Modernize 5G Solutions
14.6.2021 16:00:00 EEST | Business Wire | Press release
Robin.io, the 5G and application automation platform company, and Quanta Cloud Technology (QCT), a global data center solution provider, today announced a strategic partnership through which the companies will jointly offer solutions that significantly reduce the costs, complexities and deployment times for mobile network operators (MNOs) and communication service providers (CSPs) rolling out next-gen networks and services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210614005152/en/
The Robin.io core technologies — Multi Cluster Automation Platform (MDCAP), Robin Cloud Native Platform (CNP), Robin Cloud Native Storage (CNS) — hyper-automation that orchestrates and manages the lifecycles of bare-metal infrastructures, 3rd party appliances, Virtual Network Functions (NVFs), Cloud-native Network Functions (CNFs) and services, with built-in logging, monitoring and policy engines, for closed loop automation, managed through a single pane of glass. Robin solutions provide intuitive and declarative interfaces that auto-discover and auto-configure resources for the service’s entire life-cycle, reducing deployment complexity, time-lines and human error.
QCT works with industry leading partners to drive fundamental changes in the way telco operators plan, deploy and manage their infrastructure. They leverage their experiences as a leading cloud data center provider to develop next-gen, carrier-grade solutions targeted for 5G network infrastructures and workload-optimized solutions, such as NFVI Forwarding Platform, Ceph Storage and Enterprise 5G core network.
“With Robin’s application automation we are modernizing 5G solutions,” said Mike Yang, president of QCT. “By partnering with Robin.io, we are not only giving our mutual customers improved performance, but also pushing innovation to boost 5G application time-to-market.”
By working in close strategic partnership, QCT and Robin enable the expedited deployment of cloud-native mobile core networks in an operationally optimized solution. A QCT and Robin partnership significantly reduces the development time for Systems Integrators, CSPs and other strategic alliances by enabling a smooth path to integration and orchestration, which greatly eases the cost and operational effort needed for productization.
“Cloud-Native technology is now the standard deployments for 5G with significant economic and operational benefits for the operators,” said Partha Seetala, CEO and founder of Robin.io. “With close partnerships with QCT, we have delivered a production ready open and optimized platform for deployment and life cycle management. It’s an entire Telco Network Stack, with both CNFs and VNFs, that offers industry leading TCO.”
About Quanta Cloud Technology (QCT)
Quanta Cloud Technology (QCT) is a global data center solution provider. We combine the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operation challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.
Product lines include hyperconverged and software-defined data center solutions as well as servers, storage, switches and integrated racks with a diverse ecosystem of hardware components and software partners. QCT designs, manufactures, integrates and services cutting-edge offerings via its own global network. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. For more information, visit the QCT website at www.QCT.io.
About Robin.io
Robin.io, the 5G and application automation platform company, delivers products that automate the deployment, scaling and life cycle management of data- and network-intensive applications and for 5G service chains across edge, core and RAN. The Robin platform is used globally by companies including BNP Paribas, Palo Alto Networks, Rakuten Mobile, SAP, Sabre and USAA. Robin.io is headquartered in Silicon Valley, California. More at www.robin.io and Twitter: @robin4K8S.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005152/en/
Contact information
Media Contact:
Danny Chang (QCT)
Danny_Chang@quantatw.com
Robert Cathey
Cathey.co
+1 865-386-6118
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom